These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 14746039)

  • 41. Improving cervical cancer screening in Mexico: results from the Morelos HPV Study.
    Flores Y; Bishai D; Lazcano E; Shah K; Lörincz A; Hernández M; Salmerón J
    Salud Publica Mex; 2003; 45 Suppl 3():S388-98. PubMed ID: 14746032
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The current and future role of screening in the era of HPV vaccination.
    Myers E; Huh WK; Wright JD; Smith JS
    Gynecol Oncol; 2008 May; 109(2 Suppl):S31-9. PubMed ID: 18482556
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cervical cancer screening.
    Holcomb K; Runowicz CD
    Surg Oncol Clin N Am; 2005 Oct; 14(4):777-97. PubMed ID: 16226691
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cervical cancer screening and HPV vaccine acceptability among rural and urban women in Kilimanjaro Region, Tanzania.
    Cunningham MS; Skrastins E; Fitzpatrick R; Jindal P; Oneko O; Yeates K; Booth CM; Carpenter J; Aronson KJ
    BMJ Open; 2015 Mar; 5(3):e005828. PubMed ID: 25757944
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Workshop on screening for cancer of the uterine cervix in Central America.
    Miller AB; Robles SC
    Bull Pan Am Health Organ; 1996 Dec; 30(4):397-408. PubMed ID: 9041753
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human papillomavirus testing for primary cervical cancer screening.
    Grce M; Davies P
    Expert Rev Mol Diagn; 2008 Sep; 8(5):599-605. PubMed ID: 18785808
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.
    Goldie SJ; Kohli M; Grima D; Weinstein MC; Wright TC; Bosch FX; Franco E
    J Natl Cancer Inst; 2004 Apr; 96(8):604-15. PubMed ID: 15100338
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The present scenario of cervical cancer control and HPV epidemiology in India: an outline.
    Senapathy JG; Umadevi P; Kannika PS
    Asian Pac J Cancer Prev; 2011; 12(5):1107-15. PubMed ID: 21875253
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Screening for the prevention of cervical cancer in the era of human papillomavirus vaccination: an Australian perspective.
    Farnsworth A
    Acta Cytol; 2011; 55(4):307-12. PubMed ID: 21791898
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effective screening programmes for cervical cancer in low- and middle-income developing countries.
    Sankaranarayanan R; Budukh AM; Rajkumar R
    Bull World Health Organ; 2001; 79(10):954-62. PubMed ID: 11693978
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing.
    Wheeler CM
    Nat Clin Pract Oncol; 2007 Apr; 4(4):224-35. PubMed ID: 17392713
    [TBL] [Abstract][Full Text] [Related]  

  • 53. University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy.
    Crager SE; Guillen E; Price M
    Am J Law Med; 2009; 35(2-3):253-79. PubMed ID: 19697749
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Need for Societal Investment to Improve Cervical Cancer Outcomes in Nigeria: A commentary.
    Musa J
    Afr J Reprod Health; 2017 Dec; 21(4):17-23. PubMed ID: 29624947
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factors affecting utilization of cervical cancer prevention services in low-resource settings.
    Bingham A; Bishop A; Coffey P; Winkler J; Bradley J; Dzuba I; Agurto I
    Salud Publica Mex; 2003; 45 Suppl 3():S408-16. PubMed ID: 14746034
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cervical cancer screening programs in Latin America: current recommendations for facing elimination challenges.
    Fernández-Deaza G; Caicedo-Martínez M; Serrano B; Roura E; Castillo JS; De Sanjosé S; Bruni L; Murillo R
    Salud Publica Mex; 2022 Jul; 64(4, jul-ago):415-423. PubMed ID: 36130384
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cervical cancer, a disease of poverty: mortality differences between urban and rural areas in Mexico.
    Palacio-Mejía LS; Rangel-Gómez G; Hernández-Avila M; Lazcano-Ponce E
    Salud Publica Mex; 2003; 45 Suppl 3():S315-25. PubMed ID: 14746024
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices.
    Catarino R; Petignat P; Dongui G; Vassilakos P
    World J Clin Oncol; 2015 Dec; 6(6):281-90. PubMed ID: 26677441
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Achieving equity in cervical cancer screening in low- and middle-income countries (LMICs): Strengthening health systems using a systems thinking approach.
    Gravitt PE; Silver MI; Hussey HM; Arrossi S; Huchko M; Jeronimo J; Kapambwe S; Kumar S; Meza G; Nervi L; Paz-Soldan VA; Woo YL
    Prev Med; 2021 Mar; 144():106322. PubMed ID: 33678230
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Development of a conceptual model for interpretation of monitoring indicators of cancer screenings from the Italian National Prevention Plan].
    Zappa M; Bevere F; Braga M; Broccoli S; Cosentino M; Galeone D; Federici A; Marvulli M; Vasselli S; Venturelli F; Bellentani M; Giorgi Rossi P
    Epidemiol Prev; 2019; 43(5-6):354-363. PubMed ID: 31659883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.